Abstract
Introduction: Sodium-glucose Cotransporter-2 inhibitors (SGLT2) and Glucagon-like Peptide-1 receptor agonist (GLP-1) medications are known to reduce cardiovascular mortality through their insulin-independent mechanisms. The prescription pattern of these medications among diabetes patients is unknown. We sought to classify prescription patterns within our healthcare system and identify factors which influence these patterns. Hypothesis: We predicted that socioeconomic factors would influence the likelihood of SGLT2 or GLP-1 prescription for diabetes care. Methods: Unique encounters for diabetes care in the outpatient and inpatient setting from January 1, 2020, to December 31, 2020, were identified through a systematic query of our healthcare system’s database. We included patients >18 years old who had an A1C of ≥8%. We abstracted demographic data, SGLT2 or GLP-1 prescription status, diabetes complications and assessed the relationship between these and the likelihood of being prescribed one of the medications of interest. Results: Of the 2,746 patients included, 24.4% were prescribed either an SGLT2 or a GLP-1. Prescription status did not differ by sex. Users were more likely to be younger (mean age: 65.1 ± 9.4 years vs. 66.4 ± 9.9 years, p = 0.005); non-Hispanic (86.3%), White (77.9%), likely to live in a middle-income level zip code, and likely to have private insurance. Logistic regression of the predictors of prescription status is shown in table 1. Conclusion: Race, age, ethnicity, insurance type, and median annual household income are associated with the likelihood that a diabetes patient would be prescribed either an SGLT2 or GLP-1. Further work is warranted to identify resources and strategies to limit the disparities in prescription patterns
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call